How does your management change for patients with bone marrow failure due to a metastatic solid tumor to the marrow?

Topics: Breast Cancer • Gastrointestinal Cancers • Genitourinary Cancers • Thoracic Malignancies • Prostate Cancer • Medical Oncology

Do you offer EPO and TPO support? Do you modify your systemic therapy up front or after subsequent cycles?

Answer from: Medical Oncologist at Academic Institution

This is not an uncommon scenario in small cell lung cancer. Unfortunately, there are not much data to guide management, as most clinical trials exclude patients with abnormal counts. In this setting, I take the approach that if all other organ functions are acceptable, the bone marrow is unlikely to...

Comments

Medical Oncologist at University of Minnesota
I agree with @Apar Kishor Ganti for the small cell...

Related Questions